News

Notice of the general office of the State Health Commission on strengthening the management of diagnosis and treatment of chronic wounds (ulcers) on the body surface

2019-12-05

  In order to strengthen the management of diagnosis and treatment of chronic refractory wounds (ulcers), improve the level of diagnosis and treatment, ensure the safety of patients and the quality of diagnosis and treatment, and safeguard the health rights and interests of the people, the general office of the National Health Commission issued the notice on strengthening the management of diagnosis and treatment of chronic refractory wounds (ulcers) on December 2, 2019.

    Please click the link for details：http://www.nhc.gov.cn/yzygj/s7659/201912/602716f0471944b8b63b0adabe4546df.shtml

Previous article

None

Next article

The announcement of CFDA will effect a large collection of pharmaceutical companies

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China